Supply Chain

Acquisition expected to help provide customers with a quicker clinical trial recruitment process

Five-year, nearly $90 million deal revolves around bulk drug substance formulation for Providence’s future shot

FDA’s recommended guidance is for a system that ‘does not exist, cannot be built by 2023, and poses unacceptable security and compliance risks,’ says alliance

Biotech firm to file regulatory dossier with officials around the world

Collaboration earns Adaptimmune an initial payday of $150 million

Supply deal with Takeda to begin distribution in early 2022, pending shot approval

Drug maker to supply European Union with 60 million doses by end of Q3

Company’s prospective malaria and tuberculosis doses will be developed in Rwanda, Senegal

Meeting future expectations in pharmaceutical sustainability a key component of shipping collaboration

Project will center on equipment and technology improvements, says UK R&D and manufacturing accelerator

Wholesaler's 3PL arm to provide logistics and distribution support to potential emergency use drug for patients with critical Covid with respiratory failure

Program expands an ongoing effort at Wake Forest

Outlining five questions that should be considered when assessing if RWD is “fit for purpose” in pharma research—and ultimately clinical and pharmacy decision support

Agency hopes Pfizer-BioNTech jab approval will convince some in public to get vaccinated

Cardiff center will help produce lipids that are necessary for mRNA Covid vaccines

How the development of more quantitative and qualitative data around the patient can drive better-informed care decisions—and help avoid potential overstock scenarios that can deplete earnings

Company is also cited by SAP; meanwhile, HDA attendees get cautioned by FDA

Announcement only applies to mRNA doses at this point

CDMO’s future greater Boston facility to expand cGMP manufacturing capacity, accelerate commercial drug supply

Marks the fifth shot to receive emergency approval by Indian health authorities

Among focal points, New Jersey location will support clinical research, pharmacovigilance

Supply will start to become available in Q4 of this year, pending approval by EMA

State and regional economic-development authorities compete fiercely for siting new pharma enterprises, and holding onto the ones they have. But pharma’s stupendous growth in investment is giving all regions a boost

Sector is expected to be driven by a rise in drug development and regulatory approvals for advanced therapies

Acquisition of US partner establishes Sanofi's plan to advance messenger RNA technology for vaccines, therapeutics